Adaptive BiotechnologiesADPT
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 709
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
56% more call options, than puts
Call options by funds: $403K | Put options by funds: $259K
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
45% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 44
36% more capital invested
Capital invested by funds: $540M [Q2] → $732M (+$193M) [Q3]
7% more funds holding
Funds holding: 175 [Q2] → 187 (+12) [Q3]
4.19% less ownership
Funds ownership: 101.23% [Q2] → 97.04% (-4.19%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler David Westenberg 73% 1-year accuracy 16 / 22 met price target | 11%upside $7 | Overweight Maintained | 11 Nov 2024 |
BTIG Mark Massaro 67% 1-year accuracy 20 / 30 met price target | 27%upside $8 | Buy Maintained | 2 Oct 2024 |
Financial journalist opinion
Based on 6 articles about ADPT published over the past 30 days